Poland· PL-100323616
Pediaven NN2
A lösungen zur parenteralen ernährung, kombinationen product containing produkt złożony, registered in Poland by Fresenius Kabi Polska Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lösungen zur parenteralen ernährung, kombinationen is registered in 11 of 19 countries.
Countries holding a registration under ATC B05BA10 (lösungen zur parenteralen ernährung, kombinationen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Lösungen zur parenteralen ernährung, kombinationen · ATC B05BA10
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Produkt złożony
- Manufacturer
- Fresenius Kabi Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- B05BA10
- ATC class
- Lösungen zur parenteralen Ernährung, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991185350
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for lösungen zur parenteralen ernährung, kombinationen.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lösungen zur parenteralen ernährung, kombinationen · interactions on record
6 records
- 2 severe
- 4 moderate
Most severe, free to view
- ErdafitinibL01EN01severe
- ErdafitinibL01EX16severe
- AmfetamineN06BA01moderate
- DexamfetamineN06BA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B05BA10
Lösungen zur parenteralen ernährung, kombinationen, as other registers publish it.
- PolandAminomel 10 EBaxter Polska Sp. z o.o.
- PolandAminomel 12,5 EBaxter Polska Sp. z o.o.
- PolandAminomel NephroBaxter Polska Sp. z o.o.
- BelgiumAminomix 1 NovumFresenius Kabi
- CzechiaAMINOMIX 1 NOVUMFresenius Kabi Deutschland GmbH, Bad Homburg
- CzechiaAMINOMIX 1 NOVUMFresenius Kabi Deutschland GmbH, Bad Homburg
- CzechiaAMINOMIX 1 NOVUMFresenius Kabi Deutschland GmbH, Bad Homburg
- NetherlandsAminomix 1 Novum, oplossing voor infusieFresenius Kabi Nederland B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a9120e43-669e-4855-a523-3d2970ce9b8f GET /v1/drugs/a9120e43-669e-4855-a523-3d2970ce9b8f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do infuzji",
"source": "urpl",
"strength": "-",
"packaging": "05909991185350 ¦ Lz ¦ 103269\n10 worków 250 ml",
"substance": null,
"common_name": "Produkt złożony",
"pl_product_id": "100323616",
"pozwolenie_nr": "22020",
"auth_procedure": "DCP",
"authorisation_validity": "2026-04-11"
}See everything about lösungen zur parenteralen ernährung, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.